Similar drugsTo uncover Dosage form: & nbspPills Composition:Each tablet contains: Active components: Dry extracts:The bicuspid of stalk flowers (Didymocarpuspedicellata R. Br.) 65.0 mg; Sintered saxifraga ligulata Wall. 49,0 mg;Marenes of the heart stems (Rubia cordifolia L.) 16.0 mg;Feeds of membranous rhizomes (Cyperus scariosus R.Br.) 16.0 mg;Solomontsvet Rough Grains (Achyranthes aspera L.) 16.0 mg;Onosmum of the bracts above the aerial part (Onosma bracteatum Wall.) 16.0 mg;The vernonia of the ashy whole plant (Vemonia'cinerea (L.) Less.) 16.0 mg.Powders:Silicate of lime 16.0 mg;Mumiye (purified) 13.0 mg.Steam treated aqueous extract (1:10) from a mixture of the following plant raw materials taken in equal quantities: basil of fragrant aboveground part (Ocimum, basilicum L.), horse legumes of seeds (Dolichos biflorus L.), Tribulus terrestris L .), mimosa of shamefaced seeds (Mimosa pudica L.), the scent of the fragrant whole plant (Pavonia odorata), the horsetail of the whole plant (Equisetum arvense L.), the teak seed tree (Tectona grandis Lf seed.).Excipients: magnesium stearate 2.0 mg; cellulose microcrystalline 38.0 mg; carmellose sodium 22.0 mg; crospovidone 6.0 mg; silicon dioxide colloidal 9.0 mg. Description:Round biconvex tablets of light brown color with impregnations of lighter and darker color. Pharmacotherapeutic group:Nephrolithiasis is a herbal remedy. ATX: & nbspDrugs for the treatment of nephrourolythiasis Pharmacodynamics:The complex of biologically active substances that make up the drug Tsiston®, causes diuretic, spasmolytic, litholytic, antimicrobial and anti-inflammatory effects. Pharmacokinetics:Data on the pharmacokinetics of the multicomponent herbal preparation Cyston® in the dosage form of the tablet are not available. The activity of the drug is due to the mutually reinforcing combined effect of its components, which is typical for herbal medicines. Since the activity of the drug can not be fully attributed to any single compound, pharmacokinetic studies of multicomponent plant preparations, including Cyston® tablets, are not feasible. Indications:Complex therapy of urolithiasis, crystalluria, urinary tract infections. Contraindications:Povppennaya sensitivity to the components of the drug. Acute pain in the kidney and urinary tract. Age to 18 years. It is not recommended to use the drug at a stone size of more than 9 mm in diameter because of the threat of obstruction. Pregnancy and lactation:The use of the drug is not recommended during pregnancy and during breastfeeding (in connection withwith insufficient data to study the efficacy and safety of the drug in these conditions). If it is necessary to use the drug during lactation, breastfeeding should be discontinued. Dosing and Administration:Inside, after eating.The use of Cyston® is recommended against a background of increased fluid intake up to 2-2.5 liters per day.Adults: complex therapy of urolithiasis and crystalluria: 2 tablets 2 times a day for 4-6 months or until stones come out;prevention of recurrence after surgical removal, remote lithotripsy or spontaneous release of stones: 2 tablets 2 times a day for the first month, then 1 tablet 2 times a day for 4-5 months; complex therapy of urinary tract infections (cystitis, urethritis, pyelonephritis and others): 2 tablets 2 times a day, the duration of the course of treatment is 2-3 weeks or until the normalization of clinical symptoms and laboratory tests. The duration of treatment can be extended depending on the severity of the illness on the recommendation of the doctor. Side effects:Allergic reactions.If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor. Overdose:To date, cases of overdose have not been identified, so the symptoms of overdose are not described. To avoid overdose, follow the instructions for use. Treatment in case of accidental overdose of Cyston®: symptomatic. Interaction:The use of the drug with antibiotics helps to increase the effectiveness of therapy.Cyston® increases the bioavailability of norfloxacin. When combined with cotrioxazole in an animal experiment, Cyston® delayed the absorption of sulfamethoxazole, statistically significantly increasing its bioavailability, and accelerated the absorption of trimethoprim, without significantly affecting its bioavailability. When using these drugs simultaneously with the preparation of Cyston®, their dose may need to be adjusted. Special instructions:Since the therapeutic effect of the drug Tsiston® develops gradually, you should stop taking it when you have acute pain in the area of the kidneys and urinary tract and consult a doctor.Application of the drug in urolithiasis requires compliance with a diet with a restriction in the diet of nutrients that promote the formation of crystals of salts or stones in the urinary tract, and taking into account the characteristics of metabolism and acid-base reaction of urine.The use of the drug for urolithiasis and crystalluria does not depend on the composition of the stones and the pH of the urine. The drug is effective in oxalate, urate, phosphate, urolithiasis.With the cessation of the use of the drug Cyston ®, the pill of the "withdrawal" syndrome is not observed. In elderly patients and patients with renal insufficiency, dose adjustment is not required. Special measures when skipping one or more doses of the drug is not required. If a patient once or several times misses a drug, you should continue taking the drug at the recommended scheme in the instructions, not doubling the dose.Special precautions are not required when destroying an unused medicinal product. Effect on the ability to drive transp. cf. and fur:The drug does not affect the performance of potentially hazardous activities,requiring special attention and quick reactions (driving and other vehicles, working with moving mechanisms, dispatcher / operator work, etc.). Form release / dosage:Pills. Packaging:For 100 tablets in a plastic bottle of high density polyethylene with a screw cap. The neck of the bottle is additionally tightened with aluminum foil with the trademark of the company printed on it. Each vial with instructions for use is placed in a cardboard box. Storage conditions:In a dry place at a temperature of 10 ° C to 30 ° C.Keep out of the reach of children. Shelf life:3 years. Do not use after the expiration date. Terms of leave from pharmacies:Without recipe Registration number:P N008949 Date of registration:14.05.2010 / 20.03.2012 The owner of the registration certificate:Himalaya Drag CoHimalaya Drag Co India Manufacturer: & nbspHIMALAYA DRUG, Co. India Representation: & nbspTRANSATLANTIC INTERNATIONAL CJSC TRANSATLANTIC INTERNATIONAL CJSC Russia Information update date: & nbsp2016-01-31 Illustrated instructions × Illustrated instructions Instructions